Y-MABS THERAPEUTICS INC. - COMMON STOCK
10.41
22-November-24 16:44:58
15 minutes delayed
Stocks
+0.31
+3.07%
Today's range
9.93 - 10.49
ISIN
N/A
Source
NASDAQ
-
16 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
13 Dec 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
31 Oct 2023 07:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
18 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
17 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs Announces Publication in Cancers
16 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
21 Sep 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences in September
06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
10 Aug 2023 16:05:02 By Nasdaq GlobeNewswire
-
Y-mAbs to Participate at Upcoming Investor Conferences
02 Aug 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
01 Aug 2023 16:05:00 By Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 May 2023 09:00:00 By Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 May 2023 09:00:00 By Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 May 2023 09:00:00 By Nasdaq GlobeNewswire
-
08 May 2023 16:01:00 By Nasdaq GlobeNewswire
-
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
28 Apr 2023 09:00:00 By Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 Apr 2023 09:00:02 By Nasdaq GlobeNewswire
-
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 Apr 2023 09:00:00 By Nasdaq GlobeNewswire